IFPMA Joint Guideline on Publication of Clinical Trial Results (2017.10.30)
The IFPMA (International Federation of Pharmaceutical Manufacturers and Associations) Joint Guideline on Publication of Clinical Trial Results in Medical Journals was approved by IFPMA and entered into force on June 10, 2010. The JPMA, EFPIA, and PhRMA, as well as their member companies, have committed in this guideline that, at a minimum, they will submit the results of all company-sponsored Phase III clinical trials and other studies deemed to be medically important to peer-reviewed medical journals. The new joint guideline is intended to ensure that the results are published in peer-reviewed medical journals. This new joint guideline requires submission of all trial results within its scope, regardless of whether the results are good or bad.
This IFPMA Joint Guideline was approved by the JPMA as well as EFPIA and PhRMA prior to IFPMA approval.
This Joint Guideline underwent a minor revision on October 30, 2017.